Skip to main content
ResearchTreatments

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

By June 21, 2021November 7th, 2021No Comments

*May 2021*

The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation after progression on an EGFR tyrosine kinase inhibitor (TKI), according to results from a phase 1B/2 study presented in a poster during the American Association for Cancer Research Annual Meeting 2021.